Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Clinical Disease Activity With Long Term Natalizumab Treatment

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: natalizumab

First Posted Date: 2016-02-09

Last Posted Date: 2019-01-04

Lead Sponsor: Biogen

Target Recruit Count: 277

Registration Number: NCT02677077

Locations: 🇨🇿
Research Site, Prague, Czechia
🇧🇪
Research Site 2, Brussels, Belgium
🇧🇪
Research Site 1, Brussels, Belgium

MSPT Device Usability Study

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2016-01-27

Last Posted Date: 2016-05-04

Lead Sponsor: Biogen

Target Recruit Count: 60

Registration Number: NCT02664324

Locations: 🇺🇸
Research Site, Cleveland, Ohio, United States

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Phase 1

Terminated

Conditions: Supranuclear Palsy, Progressive

Interventions: Drug: BIIB092

First Posted Date: 2016-01-20

Last Posted Date: 2020-05-18

Lead Sponsor: Biogen

Target Recruit Count: 47

Registration Number: NCT02658916

Locations: 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

and more 10 locations

Long-Term Assessment of Remyelinating Therapy

Phase 2

Completed

Conditions: Acute Optic Neuritis

Interventions: Drug: Placebo
Drug: BIIB033 100mg/Kg

First Posted Date: 2016-01-18

Last Posted Date: 2019-09-23

Lead Sponsor: Biogen

Target Recruit Count: 52

Registration Number: NCT02657915

Locations: 🇬🇧
Research Site, London, United Kingdom

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Phase 1

Completed

Conditions: Central Nervous System (CNS) Demyelinating Disease
Multiple Sclerosis

Interventions: Biological: BIIB033
Other: Placebo

First Posted Date: 2015-12-29

Last Posted Date: 2016-10-10

Lead Sponsor: Biogen

Target Recruit Count: 24

Registration Number: NCT02641041

Locations: 🇬🇧
Research Site, Leeds, West Yorkshire, United Kingdom

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: ALKS 8700

First Posted Date: 2015-12-18

Last Posted Date: 2022-07-26

Lead Sponsor: Biogen

Target Recruit Count: 1057

Registration Number: NCT02634307

Locations: 🇺🇦
Alkermes Investigational Site, Zaporizhzhya, Ukraine

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: Tofersen

First Posted Date: 2015-12-08

Last Posted Date: 2023-07-28

Lead Sponsor: Biogen

Target Recruit Count: 176

Registration Number: NCT02623699

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 28 locations

Methodology Study of Novel Outcome Measures to Assess Progression of ALS

Completed

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2015-11-23

Last Posted Date: 2019-10-24

Lead Sponsor: Biogen

Target Recruit Count: 138

Registration Number: NCT02611674

Locations: 🇺🇸
University of California San Diego Medical Center, San Diego, California, United States
🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 18 locations

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

Phase 3

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: nusinersen

First Posted Date: 2015-11-01

Last Posted Date: 2024-10-22

Lead Sponsor: Biogen

Target Recruit Count: 292

Registration Number: NCT02594124

Locations: 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇧🇪
Universitair Kinderziekenhuis Koningin Fabiola, Brussels, Belgium
🇮🇹
Pediatric Neurology Unit, Catholic University, Essen, Italy

and more 43 locations

Plegridy Satisfaction Study in Participants

Phase 4

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS)

Interventions: Drug: peginterferon beta-1a

First Posted Date: 2015-10-27

Last Posted Date: 2023-08-31

Lead Sponsor: Biogen

Target Recruit Count: 193

Registration Number: NCT02587065

Locations: 🇮🇹
Research Site, Torino, Italy
🇮🇹
research Site, Napoli, Italy

Home Terms & Conditions Privacy Policy